Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion to Everolimus for GI Toxicity in Kidney Transplant
NCT02974686Phase 4Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of everolimus in kidney transplant rejection, sponsored by Washington University School of Medicine. Primary endpoint: Gastrointestinal Symptom Rating Scale at 3 months. Started Nov 2016; status: terminated.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02974686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974686.